Larvol Delta - ARTEMIDELung03-A-Global-Phase-III-Study-of-Rilvegostomig-or-Pembrolizumab-Plus-Chemotherapy-for-FirstLine-Treatment-of-Metastatic-Nonsquamous-NSCLC

rilvegostomig (AZD2936) - AstraZeneca

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT06627647

Jun 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next